In the case of tamoxifen and the aromatase inhibitors, one had clear data from large adjuvant trials that these agents used as monotherapies would prevent the development of the preponderance of ER + PR + HER2-negative breast cancers (Luminal A) (Perou et al., 2000). This evidence concerns the gene CYP19A1 and breast carcinoma.